drug delivery

News

Eisai moves swiftly to expand subcutaneous Leqembi label

Before it has even launched, Eisai has filed to widen subcutaneous Leqembi's label to include starting as well as maintenance dosing in Alzheimer's.

News

Dose-at-home Leqembi for Alzheimer's cleared in US

Eisai and Biogen get FDA approval for subcutaneous Leqembi. Will it help stave off growing competition from Lilly's Kisunla in Alzheimer's treatment?

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

Patients

Jonah Comstock at AAPS interviewing Mehul Desai

Challenging conventional wisdom on injectables, with Mehul D...

Mehul Desai, VP of medical affairs at Enable Injections, sat down with pharmaphorum editor-in-chief Jonah Comstock at AAPS.

News

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Neuroscience isn't listed as one of the top R&D priorities at GSK, but a new alliance with ABL Bio adds to the sense that its focus may be shifting.

News

Graphical representation of Brainshuttle antibody at the blood-brain barrier

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

Buoyed by data from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's drug from its Brainshuttle programme.

Eisai moves swiftly to expand subcutaneous Leqembi label

Dose-at-home Leqembi for Alzheimer's cleared in US

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Challenging conventional wisdom on injectables, with Mehul D...

GSK makes fresh neuroscience foray with £2bn+ ABL deal

Roche preps phase 3 for 'Brainshuttle' Alzheimer's drug

LSX2026: On promise and patience, with Hans Schambye

Using AI-driven synthetic personas to take your insights fur...

drug delivery

Editor's Picks